BUSINESS: SESEN DEADLINE: Faruqi & Faruqi LLP Securities Partner James (Josh), Wilson Encourages Investors Who Have Suffered Losses Exceeding $50,000 To Contact Him Directly To Discuss Their Options

dWeb.News Article from Daniel Webster dWeb.News

dWeb.News Article from Daniel Webster dWeb.News

Daniel Webster, dWeb.News Publisher

October 10, 2021 08: 33 ET | Source: Faruqi & Faruqi LLP

NEW YORK, Oct. 10, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sesen Bio, Inc. (“Sesen” or the “Company”) (NASDAQ: SESN) and reminds investors of the October 18, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Sesen stock or options between December 21, 2020 and August 17, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SESN.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Sesen Bio’s clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as “major”; (2) that three of Sesen Bio’s clinical investigators were found guilty of “serious noncompliance,” including “back-dating data”; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio’s clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 18, 2021, before the market opened, STAT published an article entitled “Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show.” Citing “hundreds of pages of internal documents” and “three people familiar with the matter,” the article detailed that the clinical trial for Vicineum was “marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose.”

The STAT article further stated that Vicineum had led to “worrisome side effects,” including “a serious risk for fatal, drug-induced liver injury.”

On this news, the Company’s share price fell $0. 20, or 13%, to close at $1. 31 per share on August 18, 2021, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative group may petition the Court to be appointed lead plaintiff by counsel of their choosing, or they may remain absent and do nothing. The decision to be a lead plaintiff does not affect your ability to share in any recovery.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Sesen’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. Faruqi & Faruqi LLP is the law firm responsible for this advertisement (www.faruqilaw.com). Precedent results are not indicative of a similar outcome in future matters. We would love to have a discussion about your case. All communications will be handled confidentially.

For more dWeb.News Business News: https://dweb.news/news-sections/business-news/

The post BUSINESS: SESEN DEADLINE: Faruqi & Faruqi LLP Securities Partner James (Josh), Wilson Encourages Investors Who Have Suffered Losses Exceeding $50,000 To Contact Him Directly To Discuss Their Options appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

The post BUSINESS: SESEN DEADLINE: Faruqi & Faruqi LLP Securities Partner James (Josh), Wilson Encourages Investors Who Have Suffered Losses Exceeding $50,000 To Contact Him Directly To Discuss Their Options appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

dWeb.NewsRead More

Similar Posts